Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines

被引:2
作者
Cho, Hyun-Woong [1 ]
Min, Kyung-Jin [2 ]
Kwon, Sang-Hoon [3 ]
Kim, Kidong [4 ]
Kim, Sunghoon [5 ]
Seong, Seok Ju [6 ]
Song, Yong Jung [7 ]
Lee, Keun Ho [8 ]
Lee, Shin-Wha [9 ]
Lee, Jeong-Won [10 ]
Ju, Woong [11 ]
Kim, Young Tae [5 ]
Lee, Jae Kwan [1 ]
机构
[1] Korea Univ, Guro Hosp, Dept Obstet & Gynecol, Coll Med, 148 Gurodong Ro, Seoul 08308, South Korea
[2] Korea Univ, Coll Med, Ansan Hosp, Dept Obstet & Gynecol, Ansan, South Korea
[3] Keimyung Univ, Dept Obstet & Gynecol, Sch Med, Daegu, South Korea
[4] Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, Seongnam, South Korea
[5] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[6] CHA Univ, CHA Gangnam Med Ctr, Dept Obstet & Gynecol, Seoul, South Korea
[7] Pusan Natl Univ, Dept Obstet & Gynecol, Sch Med, Yangsan, South Korea
[8] Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul St Marys Hosp, Seoul, South Korea
[9] Univ Ulsan, Asan Med Ctr, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[10] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Sch Med, Seoul, South Korea
[11] Ewha Womans Univ, Sch Med, Dept Obstet & Gynecol, Mokdong Hosp, Seoul, South Korea
关键词
Papillomavirus Vaccines; Practice Guideline; Middle Aged; Female; Male; CERVICAL INTRAEPITHELIAL NEOPLASIA; (HPV)-16/18 AS04-ADJUVANTED VACCINE; QUADRIVALENT HPV VACCINE; HPV-6/11/16/18; VACCINE; ADVISORY-COMMITTEE; CANCER VACCINE; FOLLOW-UP; IMMUNOGENICITY; SAFETY; EFFICACY;
D O I
10.3802/jgo.2021.32.e94
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review.
引用
收藏
页数:13
相关论文
共 54 条
[1]   Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study [J].
Arnheim-Dahlstrom, Lisen ;
Pasternak, Bjorn ;
Svanstrom, Henrik ;
Sparen, Par ;
Hviid, Anders .
BMJ-BRITISH MEDICAL JOURNAL, 2013, 347
[2]   Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis [J].
Bartels, Helena C. ;
Postle, James ;
Rogers, Ailin C. ;
Brennan, Donal .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (06) :777-782
[3]   Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women [J].
Bhatla, Neerja ;
Suri, Vanita ;
Basu, Partha ;
Shastri, Surendra ;
Datta, Sanjoy K. ;
Bi, Dan ;
Descamps, Dominique J. ;
Bock, Hans L. .
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (01) :123-132
[4]   Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration [J].
Bray, F. ;
Ferlay, J. ;
Laversanne, M. ;
Brewster, D. H. ;
Mbalawa, C. Gombe ;
Kohler, B. ;
Pineros, M. ;
Steliarova-Foucher, E. ;
Swaminathan, R. ;
Antoni, S. ;
Soerjomataram, I. ;
Forman, D. .
INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (09) :2060-2071
[5]   End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age [J].
Castellsague, X. ;
Munoz, N. ;
Pitisuttithum, P. ;
Ferris, D. ;
Monsonego, J. ;
Ault, K. ;
Luna, J. ;
Myers, E. ;
Mallary, S. ;
Bautista, O. M. ;
Bryan, J. ;
Vuocolo, S. ;
Haupt, R. M. ;
Saah, A. .
BRITISH JOURNAL OF CANCER, 2011, 105 (01) :28-37
[6]   Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up [J].
Chen, Wen ;
Zhao, Yun ;
Xie, Xing ;
Liu, Jihong ;
Li, Jingran ;
Zhao, Chao ;
Wang, Shaoming ;
Liao, Xueyan ;
Shou, Qiong ;
Zheng, Minghuan ;
Saah, Alfred J. ;
Wei, Lihui ;
Qiao, Youlin .
VACCINE, 2019, 37 (06) :889-897
[7]  
Committee KGCP, 2011, CLIN GUID QUADR VAL
[8]  
Committee KGCP, 2011, CLIN GUID BI VAL HPV
[9]   HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions [J].
del Pino, Marta ;
Marti, Cristina ;
Torras, Ines ;
Henere, Carla ;
Munmany, Meritxell ;
Marimon, Lorena ;
Saco, Adela ;
Torne, Aureli ;
Ordi, Jaume .
VACCINES, 2020, 8 (02)
[10]   Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial [J].
Einstein, Mark H. ;
Takacs, Peter ;
Chatterjee, Archana ;
Sperling, Rhoda S. ;
Chakhtoura, Nahida ;
Blatter, Mark M. ;
Lalezari, Jacob ;
David, Marie-Pierre ;
Lin, Lan ;
Struyf, Frank ;
Dubin, Gary .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) :3435-3445